Benjamin L. Palleiko Sells 14,400 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko sold 14,400 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $9.26, for a total value of $133,344.00. Following the sale, the chief executive officer now directly owns 266,598 shares in the company, valued at $2,468,697.48. The trade was a 5.12 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

KalVista Pharmaceuticals Stock Up 8.8 %

NASDAQ KALV opened at $10.15 on Friday. The company has a market cap of $438.63 million, a price-to-earnings ratio of -2.88 and a beta of 0.92. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.39 and a 52 week high of $16.88. The business has a 50 day moving average price of $11.04 and a 200-day moving average price of $11.99.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings data on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.04. On average, equities research analysts anticipate that KalVista Pharmaceuticals, Inc. will post -2.7 earnings per share for the current year.

Wall Street Analysts Forecast Growth

KALV has been the topic of a number of recent research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, September 9th. Needham & Company LLC reiterated a “buy” rating and issued a $32.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, September 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Monday, October 7th.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Barclays PLC boosted its position in shares of KalVista Pharmaceuticals by 418.5% during the third quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company’s stock valued at $778,000 after buying an additional 54,257 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of KalVista Pharmaceuticals by 3.1% during the third quarter. Geode Capital Management LLC now owns 830,984 shares of the specialty pharmaceutical company’s stock valued at $9,624,000 after buying an additional 24,713 shares during the last quarter. Zimmer Partners LP boosted its position in shares of KalVista Pharmaceuticals by 52.6% during the third quarter. Zimmer Partners LP now owns 95,704 shares of the specialty pharmaceutical company’s stock valued at $1,108,000 after buying an additional 33,000 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of KalVista Pharmaceuticals by 40.3% during the third quarter. Wellington Management Group LLP now owns 117,923 shares of the specialty pharmaceutical company’s stock valued at $1,366,000 after buying an additional 33,900 shares during the last quarter. Finally, State Street Corp boosted its position in shares of KalVista Pharmaceuticals by 68.1% during the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock valued at $14,725,000 after buying an additional 515,179 shares during the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).